Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Bent, M.J.
Right arrow Articles by Carpentier, A.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Bent, M.J.
Right arrow Articles by Carpentier, A.F.
Related Collections
Right arrow All Oncology
Neurology 2001;57:340-342
© 2001 American Academy of Neurology
Brief Communications

Temozolomide chemotherapy in recurrent oligodendroglioma

M.J. van den Bent, MD;, F. Keime-Guibert, MD, A.A. Brandes, MD, M.J.B. Taphoorn, MD, J.M. Kros, MD, F.A.L.M. Eskens, MD; and A.F. Carpentier, MD

From the Departments of Neuro-Oncology (Dr. Bent), Pathology (Dr. Kros), and Oncology (Dr. Eskens), University Hospital Rotterdam/Rotterdam Cancer Center, the Netherlands; Fédération de Neurologie Mazarin (Dr. Keime–Guibert), Hôpital de la Salpetrière, Paris, France; Divisione di Oncologia Medica (Dr. Brandes), Azienda Ospedale, Università di Padova, Italy; and Department of Neurology (Dr. Taphoorn), University Medical Center Utrecht, the Netherlands.

Address correspondence and reprint requests to Dr. M.J. van den Bent, Department of Neuro-Oncology, University Hospital Rotterdam/Rotterdam Cancer Center, PO Box 5201, 3008 AE Rotterdam, the Netherlands; e-mail: bent{at}neuh.azr.nl

The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.




This article has been cited by other articles:


Home page
 Neuro OncolHome page
M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al.
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
Neuro Oncology, April 1, 2009; 11(2): 167 - 175.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
J. Clin. Oncol., March 10, 2006; 24(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. H.J.M. Triebels, M. J.B. Taphoorn, A. A. Brandes, J. Menten, M. Frenay, A. Tosoni, J. M. Kros, E. B.-t. Stege, R. H. Enting, A. Allgeier, et al.
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas
Neurology, September 14, 2004; 63(5): 904 - 906.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Lebrun, D. Fontaine, A. Ramaioli, F. Vandenbos, S. Chanalet, M. Lonjon, J. F. Michiels, V. Bourg, P. Paquis, M. Chatel, et al.
Long-term outcome of oligodendrogliomas
Neurology, May 25, 2004; 62(10): 1783 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al.
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Ann. Onc., December 1, 2003; 14(12): 1715 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M.J. van den Bent, M.J.B. Taphoorn, A.A. Brandes, J. Menten, R. Stupp, M. Frenay, O. Chinot, J.M. Kros, C.C.D. van der Rijt, Ch.J. Vecht, et al.
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
J. Clin. Oncol., July 1, 2003; 21(13): 2525 - 2528.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Jaeckle, K. R. Hess, W.K. A. Yung, H. Greenberg, H. Fine, D. Schiff, I. F. Pollack, J. Kuhn, K. Fink, M. Mehta, et al.
Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study
J. Clin. Oncol., June 15, 2003; 21(12): 2305 - 2311.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. J. Bodell, N. W. Gaikwad, D. Miller, and M. S. Berger
Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide: Implications for the Treatment of Low-Grade Adult and Pediatric Brain Tumors
Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 545 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. J. van den Bent, O. Chinot, W. Boogerd, J. Bravo Marques, M. J. B. Taphoorn, J. M. Kros, C. C. D. van der Rijt, C. J. Vecht, N. De Beule, and B. Baron
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
Ann. Onc., April 1, 2003; 14(4): 599 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
M. van den Bent, O.-L. Chinot, and J. G. Cairncross
Recent developments in the molecular characterization and treatment ofoligodendroglial tumors
Neuro Oncology, April 1, 2003; 5(2): 128 - 138.
[Abstract] [PDF]